Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations Business Wire NEW YORK & PETACH TIKVAH, Israel -- February 27, 2013 BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News. Rasheda Ali, a member of BrainStorm’s advisory board and revered author and daughter of renowned boxer Muhammad Ali, discussed BrainStorm’s promising ALS clinical trials last week on NBC NY and Current TV’s Viewpoint. She was also interviewed on Fox News’ Geraldo at Large and Neil Cavuto shows. In her various interviews, Ms. Ali stated that BrainStorm’s Phase I/II ALS clinical trial results with its NurOwn™ stem cell candidate exceeded scientists’ expectations, surpassing the goal of confirming safety by also showing initial signs of clinical improvement. She also discussed BrainStorm’s recent acceleration to a Phase IIa trial by the Israeli Ministry of Health. Ms. Ali’s interviews can be viewed at the following links: NBC NY: http://bit.ly/Xam0rG. Current TV Viewpoint: http://bit.ly/13VDZRY About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com. Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Contact: BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI) Mr. Alon Natanson, CEO Phone: +972-3-9236384 email@example.com www.brainstorm-cell.com
Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations
Press spacebar to pause and continue. Press esc to stop.